Researchers have discovered that vitamin B2, also known as riboflavin, helps cancer cells survive by protecting them from ferroptosis, a type of cell death caused by iron-driven oxidative damage. The study, published in Nature Cell Biology, found that vitamin B2 supports a protein called FSP1, which strengthens the antioxidant defenses of tumor cells and prevents […]
Vitamin B2 Found to Help Cancer Cells Resist Cell Death Read More »
A study published in Communications Biology has identified pyruvate carboxylase (PC) as a key driver of metabolic changes in epithelial ovarian cancer. Researchers found that high PC levels are linked to more advanced disease, metastasis, recurrence, and poorer survival. The study shows that PC helps cancer cells build up fats by boosting the production of triglycerides
On May 13, 2026, the FDA approved an all-oral combination of decitabine/cedazuridine (Inqovi) and venetoclax (Venclexta) for adults with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older or unable to receive intensive chemotherapy. The approval was based on results from the phase 2 ASCERTAIN-V trial involving 101 patients. The study showed
FDA Approves All-Oral Inqovi and Venetoclax Combination for Older Patients With AML Read More »
High-level results from the phase 3 VOLGA trial show that combining durvalumab (Imfinzi) with enfortumab vedotin (Padcev) before surgery significantly improves survival for patients with muscle-invasive bladder cancer who cannot receive or choose not to receive cisplatin chemotherapy. The treatment improved both event-free survival and overall survival compared with surgery alone. Another treatment group using
New 3-year results from the phase 3 ENVISION trial show that Zusduri (mitomycin for intravesical solution) can provide long-lasting disease control for patients with recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer. The study found that nearly two-thirds of patients who achieved a complete response after treatment remained cancer-free three years later. Patients received only a single
Phase 3 ENVISION Trial Shows Long-Term Bladder Cancer Control With Zusduri Read More »
A 10-year phase 2 study published in the journal Blood found that ibrutinib alone can provide long-lasting benefits for patients with chronic lymphocytic leukemia (CLL), including those with high-risk disease features. The study included 84 patients who were either newly diagnosed or had relapsed disease, many of whom had TP53 abnormalities or unmutated IGHV, both
10-Year Study Shows Long-Term Benefits of Ibrutinib in Chronic Lymphocytic Leukemia Read More »
A new study shows that CRISPR gene editing may help protect patients with Acute Myeloid Leukemia from the harmful side effects of intensive cancer treatment. In the VBP101 trial, researchers used CRISPR-Cas9 to remove the CD33 protein from donor stem cells before transplant. This created a new blood and immune system that could resist damage
CRISPR-Edited Stem Cells May Protect AML Patients From Treatment Toxicity Read More »
The U.S. Food and Drug Administration has granted accelerated approval to Sonrotoclax for adults with relapsed or refractory Mantle Cell Lymphoma who have already received at least two previous treatments, including a BTK inhibitor. The approval was based on results from the BGB-11417-201 trial involving 103 patients whose disease had returned after standard therapies. The
FDA Approves Sonrotoclax for Previously Treated Mantle Cell Lymphoma Read More »
Researchers have developed a new way to eliminate harmful “zombie cells” linked to cancer and aging. These senescent cells stop dividing but remain active, releasing substances that can damage tissue and help tumors spread. Scientists discovered that the cells survive by overproducing GPX4, a protein that protects them from Ferroptosis, a form of cell death
New Therapy Targets “Zombie Cells” to Slow Cancer Growth and Aging Read More »
A Phase 1/2 study found that combining Belantamab mafodotin with the KRd regimen (carfilzomib, lenalidomide, and dexamethasone) produced strong and durable responses in patients with relapsed or refractory multiple myeloma. Researchers tested a new dosing schedule for belamaf, giving the drug every eight weeks instead of every three weeks to reduce eye-related side effects while
Belamaf Quadruplet Therapy Shows Strong Responses in Relapsed Multiple Myeloma Trial Read More »